| |
| When the National Cancer Act was signed on Dec. 23, 1971, it infused record amounts of federal dollars into research labs around the country —and helped transform cancer prevention, detection, diagnosis, treatment, and survivorship. Current and former Winship leaders reflect on the 50 years of progress since the act was signed and how it has made a difference in the lives of people affected by cancer. | Read More |
| |
| | | | | Video: Happy holidays from Winship | Winship leadership team members Sagar Lonial, MD, Kimberly Kerstann, PhD, Adam Marcus, PhD, Lana Uhrig, PhD, and Suresh Ramalingam, MD, take a moment to wish the Winship community a healthy and happy holiday season and to thank teams for their contributions to another year of extraordinary contributions to patient care, research, and education.
| Watch Video | |
|
| |
| | Harvey receives Fulbright Specialist Award | R. Donald Harvey, PharmD, has received a Fulbright Specialist Award in support of his collaboration with Nigeria's Project PINK BLUE. As a part of this effort, Harvey spent two weeks in Nigeria in early December meeting with partners and participating in training oncology pharmacists.
| Read More | |
| | | |
| |
| | Bostick to retire | Roberd "Robin" Bostick, MD, MPH, professor of epidemiology at Rollins School of Public Health, will retire on Dec. 31 after nearly two decades at Emory. Bostick helped establish Winship's Cancer Prevention and Control Program and served as the program’s leader for eight years until 2015. His research focused on diet and cancer and was supported by more than $53 million in research grants.
| View Profile | |
| | | |
| |
| | Sandy receives Daisy Award | Keisha Sandy, RN, BSN, OCN, a unit nurse educator in the infusion center on Winship's Clifton Road campus, has received a Daisy Award, which honors nurses who define patient family care. Sandy was nominated for the award for her outstanding work helping our patients navigate their treatment and receive the best experience possible.
| About the Daisy Foundation | |
| | | | Jansen highlighted among Emory’s best and brightest | Carey Jansen, a cancer biologist and researcher in Emory's MD/PhD program, is featured among 16 of Emory’s best and brightest students. Jansen's research focuses on immune mechanisms in cancer development and treatment, as well as immunotherapy development.
| Read More | |
|
| |
| | | | | Winship spaces full of holiday cheer | Winship teams showed off their creativity and holiday spirit this season, transforming offices and clinical areas into winter wonderlands. Pictured: treescapes from Winship's infusion center on the Clifton Road campus.
| View More Photos | |
|
| |
| |
| Below are four selected Winship publications out of 48 published over the past week: |
| |
|
| Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Hancock BA, Kassem N, Helft P, O'Neil B, Storniolo AMV, Badve S, Miller KD, Radovich M. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology. 2021; JCO2101657. PubMed PMID: 34910554. | View in PubMed |
| |
|
| Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovic A, Chen HX, Sharon E, Lesinski GB, Azad NS. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. The Journal of Clinical Investigation. 2021; 131(24). PubMed PMID: 34907910. | View in PubMed |
| |
|
| Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2021; PubMed PMID: 34882781. | View in PubMed |
| |
|
| Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin A, Keller FG, Shukla N. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Advances. 2021; 5(24):5519-5524. PubMed PMID: 34559223. | View in PubMed |
| |
| |
| A selection of media stories and news coverage for Winship Cancer Institute. |
| |
| You are receiving Winship Roundup as a member or employee of Winship Cancer Institute. If you wish to unsubscribe, please email Winship Communications.
Emory Home |
Emory News Center |
Give to Emory |
Contact Emory Have a story for Winship Roundup? Submit your suggestion via email. © 2021 Winship Cancer Institute of Emory University |
1365 Clifton Rd. NE, Bldg. C, Atlanta, Georgia 30322 | |
|